-
-
-
-
-
-
-
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
-
-
-
-
-
-
-
Blueprint Medicines (BPMC) Appoints Habib Dable to its Board
-
-
-
-
-
-
-
Blueprint Medicines (BPMC) PT Raised to $139 at Wedbush, Following Strategic Business Update
-
-
-
-
-
-
-
After-Hours Stock Movers 12/11: (PTI) (KMG) Higher; (PPHM) (CASY) (OAS) Lower (more...)
-
-
-
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

